A potential gamechanger in stress urinary incontinence

21-03-2024 – Our project leader Deana Mohr-Haralampieva of MUVON published an article in the medical journal, Leading Opinions: Gynäkologie & Geburtshilfe, a Universimed publication.

Wysszurich keyvisual muvon

Stress urinary incontinence is a major health issue that affects over 200 million people worldwide, but is currently not receiving the focus and attention it should. lt has a severe impact on physical and psychological health, and imposes a high financial burden on affected individuals, healthcare systems and society.

MUVON Therapeutics, a spin-off from the University of Zurich, is working towards breaking the stigma around stress urinary incontinence and developing a novel regenerative tissue engineering therapy with the goal of providing a safe and effective cure to help these patients regain control.